US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

A provision in a Trump executive order on drug pricing looking to limit anti-competitive behavior seems largely benign. (Shutterstock)

More from Pricing Debate

More from Compliance